That money from P&G is for collaborative work, it may cost them (in internal R&D expenses) that much. It is positive that they are expanding their drug delivery systems, but profits come from existing products (particularly hormone replacement therapy) which seems to have stalled. The problem Wyeth had was supposed to enhance NOVN's position (see some of my prior posts on that subject), it has not, so I think that on second look and after the normal CC hype, NOVN will drift back to the low $8 area.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.